SMSapna Bamrah Morris

Sapna Bamrah Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sapna Bamrah Morris has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Kofman

    1 shared publication
  • Aaron T. Curns

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication
  • Alexandra M. Oster

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication
  • Alfonso Hernandez

    Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA

    1 shared publication
  • Alicia H Chang

    Los Angeles County Department of Public Health Tuberculosis Control Program, Los Angeles, California, United States of America

    1 shared publication
  • Alicia M. Fry

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Tuberculosis Preventive Treatment And The Incidence Of Tuberculosis And Death Among Adults With HIV In Namibia: A Retrospective Cohort Study

    by Nunurai Ruswa, Gunar Gunther, Edwin Sithole, Sapna Morris, Flavia Mugala, Ismael Katjitae, James Seddon, Timothy Rennie, Mareli M. Claassens

    Background: Tuberculosis (TB) preventive treatment (TPT) reduces TB burden in people living with HIV (PLHIV). We assessed TB disease and all-cause mortality in adults in HIV care in Namibia in relation to their TPT exposure.Methods: In this retrospective cohort study, we used secondary electronic records from Namibian Ministry of Health HIV clinics and TB registers, probabilistically linked with Registry Plus LinkPlus, for adults (≥15 years) enrolled in HIV care in 2002–2022 and followed up to 2024. Rate ratios, and flexible parametric survival models with time-varying TPT exposure, were fitted in Stata 18. A 12-month landmark analysis of all-cause mortality addressed residual immortal time bias.Findings: Of 309,142 individuals, 199,337 (64·5%) were female, median age was 34 years (IQR 28–41), and 200,806 (65·0%) received TPT, contributing 1,992,845 person-years to the TB analysis and 2,131,798 to the mortality analysis. Crude TB incidence was 1·00 per 100 person-years (PY) with TPT versus 3·90 in those without TPT (incidence rate ratio 0·26, 95% CI 0·25–0·26). Mortality rate was 0·56 versus 1·60 per 100 PY, respectively (rate ratio 0·35, 95% CI 0·34–0·36). Adjusted for antiretroviral therapy (ART), sex, age, co-trimoxazole prophylaxis, and WHO stage, ART plus TPT reduced TB by 66% versus ART alone (adjusted hazard ratio 0·34, 95% CI 0·32–0·36). In the 12-month landmark analysis (n=251,202), TPT initiation by 12 months was associated with 13% lower mortality (0·87, 0·83–0·91).Interpretation: In this national cohort, TPT was associated with substantially lower TB incidence, particularly when given with ART, and with a smaller but significant reduction in all-cause mortality, supporting continued investment in timely ART and TPT in high TB burden settings.

  • C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?

    by Patrick K Moonan, Ann Buff, Subhadra Nandakumar, Sapna Bamrah Morris

  • Open Access

    Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019—United States, January 17–February 29, 2020

    by Olivia L. McGovern, Mark Stenger, Sara E. Oliver, Tara C. Anderson, Cheryl Isenhour, Matthew R. Mauldin, Nia Williams, Eric Griggs, Tonny Bogere, Chris Edens, et al.

    The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020. In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17−February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios. A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures. These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.


  • Multisystem Inflammatory Syndrome in Adults

    by Mark W. Tenforde, Sapna Bamrah Morris


  • Top Cited Papers

    Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020

    by Sapna Bamrah Morris, Noah G. Schwartz, Pragna Patel, Lilian Abbo, Laura Beauchamps, Shuba Balan, Ellen H. Lee, Rachel Paneth-Pollak, Anita Geevarughese, Maura K. Lash, et al.


  • Coronavirus Disease 2019 (COVID-19) Prevalences Among People Experiencing Homelessness and Homelessness Service Staff During Early Community Transmission in Atlanta, Georgia, April–May 2020

    by Jane C Yoon, Martha P Montgomery, Ann M Buff, Andrew T Boyd, Calla Jamison, Alfonso Hernandez, Kristine Schmit, Sarita Shah, Sophia Ajoku, David P Holland, et al.

    Background: In response to reported coronavirus disease 2019 (COVID-19) outbreaks among people experiencing homelessness (PEH) in other US cities, we conducted multiple, proactive, facility-wide testing events for PEH living sheltered and unsheltered and homelessness service staff in Atlanta, Georgia. We describe the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and associated symptoms, and review shelter infection prevention and control (IPC) policies. Methods: PEH and staff were tested for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) during 7 April–6 May 2020. A subset of PEH and staff was screened for symptoms. Shelter assessments were conducted concurrently at a convenience sample of shelters using a standardized questionnaire. Results: Overall, 2875 individuals at 24 shelters and 9 unsheltered outreach events underwent SARS-CoV-2 testing, and 2860 (99.5%) had conclusive test results. The SARS-CoV-2 prevalences were 2.1% (36/1684) among PEH living sheltered, 0.5% (3/628) among PEH living unsheltered, and 1.3% (7/548) among staff. Reporting fever, cough, or shortness of breath in the last week during symptom screening was 14% sensitive and 89% specific for identifying COVID-19 cases, compared with RT-PCR. Prevalences by shelter ranged 0–27.6%. Repeat testing 3–4 weeks later at 4 shelters documented decreased SARS-CoV-2 prevalences (0–3.9%). Of 24 shelters, 9 completed shelter assessments and implemented IPC measures as part of the COVID-19 response. Conclusions: PEH living in shelters experienced a higher SARS-CoV-2 prevalence compared with PEH living unsheltered. Facility-wide testing in congregate settings allowed for the identification and isolation of COVID-19 cases, and is an important strategy to interrupt SARS-CoV-2 transmission.


  • Open Access

    Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness

    by Nwabunie Nwana, Suzanne M Marks, Edward Lan, Alicia H Chang, Michael Holcombe, Sapna Bamrah Morris

    To investigate treatment outcomes and associated characteristics of persons experiencing homelessness who received 12-weekly doses of directly observed isoniazid and rifapentine (3HP/DOT) treatment for latent TB infection (LTBI). Among homeless persons treated with 3HP/DOT during July 2011 –June 2015 in 11 U.S. TB programs, we conducted descriptive analyses of observational data, and identified associations between sociodemographic factors and treatment outcomes. Qualitative interviews were conducted to understand programmatic experiences. Of 393 persons experiencing homelessness (median age: 50 years; range: 13–74 years), 301 (76.6%) completed treatment, 55 (14.0%) were lost to follow-up, 18 (4.6%) stopped because of an adverse event (AE), and 19 (4.8%) stopped after relocations or refusing treatment. Eighty-one (20.6%) had at least one AE. Persons aged ≥65 were more likely to discontinue treatment than persons aged 31–44 years. Programs reported difficulty in following up with persons experiencing homelessness because of relocations, mistrust, and alcohol or drug use. This study demonstrates the feasibility of administering the 3HP/DOT LTBI regimen to persons experiencing homelessness, a high-risk population.


  • Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands

    by Sundari R. Mase, John A. Jereb, Daniel Gonzalez, Fatma Mbbs Martin, Charles L. Daley, Dorina Mbbs Fred, Ann M. Loeffler, Lakshmy R. Menon, Sapna Bamrah Morris, Richard Brostrom, et al.

    Background: In the Federated States of Micronesia and then the Republic of the Marshall Islands (RMI), levofloxacin pharmacokinetics were studied in children receiving directly observed once-daily regimens (10 mg/kg, age >5 years; 15–20 mg/kg, age ≤5 years) for either multidrug-resistant tuberculosis disease or latent infection after multidrug-resistant tuberculosis exposure, to inform future dosing strategies. Methods: Blood samples were collected at 0 (RMI only), 1, 2 and 6 hours (50 children, aged 6 months to 15 years) after oral levofloxacin at >6 weeks of treatment. Clinical characteristics and maximal drug concentration (Cmax) of levofloxacin, elimination half-life and area under the curve from 0 to 24 hours (AUC0–24 hours × μg/mL) were correlated to determine the optimal dosage and to examine associations. Population pharmacokinetics and target attainment were modeled. With results from the Federated States of Micronesia, dosages were increased in RMI toward the target Cmax for Mycobacterium tuberculosis, 8–12 µg/mL. Results: Cmax correlated linearly with per-weight dosage. Neither Cmax nor half-life was associated with gender, age, body mass index, concurrent medications or predose meals. At levofloxacin dosage of 15–20 mg/kg, Cmax ≥8 µg/mL was observed, and modeling corroborated a high target attainment across the ratio of the area under the free concentration versus time curve to minimum inhibitory concentration (fAUCss,0–24/MIC) values. Conclusions: Levofloxacin dosage should be 15–20 mg/kg for Cmax ≥8 µg/mL and a high target attainment across fAUCss,0–24/MIC values in children ≥2 years of age.


  • Tuberculosis among the homeless, United States, 1994–2010

    by S. Bamrah, R. S. Yelk Woodruff, K. Powell, S. Ghosh, J. S. Kammerer, M. B. Haddad

    OBJECTIVES: 1) To describe homeless persons diagnosed with tuberculosis (TB) during the period 1994–2010, and 2) to estimate a TB incidence rate among homeless persons in the United States. METHODS: TB cases reported to the National Tuberculosis Surveillance System were analyzed by origin of birth. Incidence rates were calculated using the US Department of Housing and Urban Development homeless population estimates. Analysis of genotyping results identified clustering as a marker for transmission among homeless TB patients. RESULTS: Of 270 948 reported TB cases, 16 527 (6%) were homeless. The TB incidence rate among homeless persons ranged from 36 to 47 cases per 100 000 population in 2006–2010. Homeless TB patients had over twice the odds of not completing treatment and of belonging to a genotype cluster. US- and foreign-born homeless TB patients had respectively 8 and 12 times the odds of substance abuse. CONCLUSIONS: Compared to the general population, homeless persons had an approximately 10-fold increase in TB incidence, were less likely to complete treatment and more likely to abuse substances. Public health outreach should target homeless populations to reduce the excess burden of TB in this population.